Khaled bin Mohamed bin Zayed chairs Emirates Genome Council meeting
ABU DHABI (ALETIHAD)His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, has chaired the meeting of the Emirates Genome Council.During the meeting, the board discussed plans to prioritise precision medicine initiatives that leverage genomic data to actively enhance public health outcomes for the UAE population, advance the efficiency of the UAE healthcare system, drive economic and industry growth, and further establish the UAE as a global hub for precision medicine through the advancement of R&D.His Highness Sheikh Khaled bin Mohamed bin Zayed reaffirmed that the UAE leadership is committed to further advancing the health and wellbeing of the community and emphasised the importance of research and development in the fields of longevity, precision medicine and preventative care in enhancing public health.His Highness praised efforts to further advance the UAE as a leader at the forefront of global genomic research and application that prioritises health outcomes and enhances quality of life.
New population screening programmes During the meeting, His Highness endorsed new population screening programmes that expand the utilisation of genomic data and accelerate genome-driven personalised healthcare in the UAE. The programmes include newborn genetic screenings, enhanced screenings of adult participants in the Emirati Genome Program, provision of personalised fertility programmes, and cardiovascular genetic screening.The newborn genetic screening programme will assess genetic conditions with available treatments and early intervention options for infants, assessing 733 genes to test for more than 800 conditions.Population disease screenings, for adults participating in the Emirati Genome Program, aim to further identify actionable and relevant conditions for UAE Nationals, by assessing 94 genes linked to more than 50 genetic conditions.The personalised fertility programme assesses 186 genes linked to more than 130 genetic conditions, to provide personalised medicine recommendations and treatments for couples.Cardiovascular screenings will provide genetic diagnosis and treatment, as well as early prevention, for cardiovascular related conditions through the assessment of more than 800 genes linked to more than 100 genetic conditions.
T2T Emirati Reference Genome study His Highness was briefed on the completion of the landmark Telomere-to-Telomere (T2T) Emirati Reference Genome study aimed at advancing precision medicine for communities in the UAE. The study, by the Department of Health – Abu Dhabi, in collaboration with Khalifa University and M42, bridges critical gaps in genomic data and provides a vital resource that enhances the ability to compare with other reference genomes, supporting the advancement of disease research, pharmacogenomics and the development of Emirati-specific targeted therapies.
Premarital Genetic Screening Programme updateHis Highness was also briefed on the progress of the Premarital Genetic Screening Programme, which was nationally implemented from January 1, 2025 by the Ministry of Health and Prevention, in collaboration with the Department of Health – Abu Dhabi, Emirates Heath Services, Dubai Health Authority, and strategic partners. To date, it has supported 2,428 couples, finding more than 92 per cent genetically compatible through comprehensive genetic screening of 570 genes linked to more than 840 genetic disorders. Couples who required additional support were provided personalised genetic counselling to assess and diagnose risk factors and offer potential solutions to support family planning decisions.The programme aims to safeguard community members from hereditary diseases and empower couples to utilise genetic data to make informed decisions in family planning, preserving the health and wellbeing of community members and ensuring a healthier future for generations to come.
Emirati Genome Program progressHis Highness was also updated on the progress of the Emirati Genome Program, which has collected more than 700,000 genetic samples from citizens across the nation, marking significant progress towards the overall target of 1 million. In addition, the Emirati Genome Program has completed the collection of 100,000 samples from participants from different nationalities for a new initiative that leverages the UAE's advanced genomic capabilities. The project, in collaboration with M42, helps reduce gaps in genomic data globally by providing insights into genetic mutations affecting over 2.5 billion people across different ethnicities, with the aim to drive further collaboration on precision medicine research and solutions.The Emirati Genome Program is a key project under the National Genome Strategy and will support the transformation of healthcare services in the UAE by providing high-quality genetic data that enables researchers, physicians and scientists to identify the causes of genetic diseases, understand the type of genetic mutations, anticipate susceptibility to some diseases, and develop effective personalised healthcare plans.
The meeting was attended by His Excellency Mohammad Al Gergawi, UAE Minister of Cabinet Affairs; Her Excellency Sarah bint Yousef Al Amiri, UAE Minister of Education; His Excellency Omar bin Sultan Al Olama, UAE Minister of State for Artificial Intelligence, Digital Economy and Remote Work Applications; His Excellency Mansour Ibrahim Al Mansouri, Chairman of the Department of Health – Abu Dhabi; His Excellency Saif Saeed Ghobash, Secretary General of the Abu Dhabi Executive Council; His Excellency Dr Amer Ahmed Al-Sharif, the CEO of Dubai Health and President of Mohammed Bin Rashid University of Medicine and Health Sciences; and His Excellency Dr Yousif Mohammed Al-Serkal, Director-General of Emirates Health Services.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Etihad
4 days ago
- Al Etihad
Cleveland Clinic Abu Dhabi receives global recognition for nursing excellence
7 Aug 2025 13:58 ABU DHABI (ALETIHAD) Cleveland Clinic Abu Dhabi (CCAD) has received two international honours for nursing excellence. Four of its acute care units were awarded the PRISM Award by the Academy of Medical-Surgical Nurses, and its Intensive Care Unit received the renowned Beacon Award for Excellence from the American Association of Critical-Care Nurses. These awards reflect the hospital's continuous commitment to high-quality care and advanced nursing practices that ensure the best outcomes for Clinic Abu Dhabi is the first hospital in the UAE, and only the fourth outside the United States, to receive the PRISM Award, setting a new benchmark for nursing excellence in the region. This milestone highlights not only the hospital's clinical strength but also the calibre of its nursing leadership, professional practice, and commitment to development, empowerment, and a collaborative environment where nurses can hospital's Intensive Care Unit also received the Beacon Award for Excellence, a distinction that recognises hospital units that employ evidence-based practices to improve outcomes for patients and families. The Beacon Award reflects the high standards upheld by Cleveland Clinic Abu Dhabi's critical care the vital role nurses play within the healthcare system, Dr. Georges-Pascal Haber, CEO of Cleveland Clinic Abu Dhabi, emphasised: 'Nurses are the backbone of quality healthcare. At Cleveland Clinic Abu Dhabi, our nurses combine compassion with clinical expertise and the latest innovations to deliver care that truly changes lives. Their dedication to improving outcomes and elevating the patient's experience is what sets our care apart. These awards are not just acknowledgements; they reflect the trust our patients place in us every day, and the continuous drive of our nursing team to raise the bar in healthcare delivery.'Beth Govero, Chief Nursing Officer, Cleveland Clinic Abu Dhabi, said: 'These distinguished international recognitions stand as a testament to the expertise, perseverance, and passion of our nursing team. Nurses form the cornerstone of effective healthcare delivery, and their relentless pursuit of quality ensures exceptional care for every patient. These recognitions celebrate not only their hard work but also our collective efforts to create a supportive environment where nurses are empowered to lead, innovate, and continually advance patient care here in the UAE and beyond.'Last year, Cleveland Clinic Abu Dhabi was redesignated with the coveted Magnet® designation from the American Nurses Credentialing Centre (ANCC). Widely regarded as the gold standard for nursing excellence, this recognition highlights the hospital's commitment to transformational leadership, innovation in clinical practice, and a culture that prioritises professional development and patient-centred care. Cleveland Clinic Abu Dhabi was the first and the youngest hospital in the UAE to receive this designation in the same year, the hospital hosted its inaugural Nursing Conference, a pivotal event that brought together nursing professionals from across the region to deepen their expertise and strengthen their practice. By fostering meaningful knowledge exchange and collaboration, the conference empowered registered nurses, nurse practitioners, midwives, and clinical specialists to expand their skills and engage with leading international experts, reinforcing their essential role in delivering exceptional patient care. Building on that success, the hospital will host the second conference later this November, reinforcing its commitment to advancing nursing excellence. Cleveland Clinic Abu Dhabi is dedicated to nursing excellence and achieving superior patient outcomes. As it continues to advance this mission, it remains committed to empowering nurses as the cornerstone of transformative, patient-centred care. Source: Aletihad - Abu Dhabi
Al Etihad
5 days ago
- Al Etihad
TII, Quantinuum partner to advance next-generation quantum computing development
7 Aug 2025 11:13 ABU DHABI (ALETIHAD)The Technology Innovation Institute (TII), the applied research arm of Abu Dhabi's Advanced Technology Research Council (ATRC), has announced a strategic agreement with Quantinuum, a world leader in quantum computing, to accelerate the development and benchmarking of next-generation quantum computing algorithms and commercial applications in the United Arab Emirates (UAE).The agreement grants TII's researchers access to Quantinuum's quantum computing systems, which are recognised for having high operational fidelity. This includes access to Helios, the company's upcoming next-generation system, which is expected to demonstrate improvements in gate fidelity and qubit connectivity. This expands TII's diverse ecosystem of partner platforms, which includes in-house developed superconducting quantum chips, IonQ's trapped-ion processors, and access via AWS Braket to devices from QUERA, Rigetti, and IQM, among strategic agreement enables TII to combine state-of-the-art quantum computing systems and research efforts to develop better quantum algorithms, marking an important step in strengthening the UAE's growing position as a global leader in science and technology. Focused on advancing quantum computing applications across diverse domains of regional and global significance, the partnership's key research areas include: - Chemistry and Materials Science: Estimating quantum system properties, such as ground-state energy, for advancements in chemistry and materials, and simulating complex many-body quantum systems, such as superconductors.- Classical-to-Quantum Data Integration: Identifying efficient methods to encode classical data into quantum states, such as for image processing and data throughput.- Complex Optimisation Problems: Combining Quantinuum's industry-leading fidelity with TII's advanced algorithmic techniques for solving large combinatorial optimisation problems using very few collaboration is also pivotal in training the next generation of quantum algorithm developers, equipping the UAE and the broader region to harness emerging quantum technologies effectively."The agreement with Quantinuum represents a significant step forward in our mission to advance quantum research," said Dr. Leandro Aolita, Chief Researcher of TII's Quantum Research Centre. "With access to cutting-edge quantum hardware like Helios, we remain at the forefront of quantum research and innovation, further solidifying the UAE's status as a leading technology and innovation hub." "Quantinuum's partnership with TII marks a powerful alignment of vision and capability," said Dr. Avinash 'Nash' Palaniswamy, Chief Commercial Officer at Quantinuum. "We remain deeply committed to fostering strong partnerships across the region, uniting quantum computing trailblazers with our best-in-class systems to anchor global ecosystems, accelerate research and development, and unlock transformative value for users." Source: Aletihad - Abu Dhabi
Al Etihad
5 days ago
- Al Etihad
Harvard research on reversing Alzheimer's reveals lithium as potential key
6 Aug 2025 22:51 ABU DHABI (ALETIHAD)A decade of investigation by scientists at Harvard Medical School have revealed that the loss of the metal lithium plays a powerful role in Alzheimer's disease, a finding that could lead to earlier detection and new treatments for the disease that affects memory and cognitive led by Bruce A. Yankner, professor of genetics and neurology at Harvard Medical School, reported that they were able to reverse the disease in mice and restore brain function with small amounts of the compound lithium orotate, enough to mimic the metal's natural level in the brain. Their study appeared Wednesday in the journal findings are based on a series of experiments in mice and on analyses of human brain tissue and blood samples from individuals in various stages of cognitive scientists found that lithium loss in the human brain is one of the earliest changes leading to Alzheimer's, while in mice, similar lithium depletion accelerated brain pathology and memory team further found that reduced lithium levels stemmed from binding to amyloid plaques and impaired uptake in the brain. In a final set of experiments, the team found that a novel lithium compound that avoids capture by amyloid plaques restored memory in mice. The results unify decades-long observations in patients, providing a new theory of the disease and a new strategy for early diagnosis, prevention, and an estimated 400 million people worldwide, Alzheimer's disease involves an array of brain abnormalities — such as clumps of the protein amyloid beta, neurofibrillary tangles of the protein tau, and loss of a protective protein called REST — but these never explained the full story of the instance, some people with such abnormalities show no signs of cognitive decline. And recently developed treatments that target amyloid beta typically don't reverse memory loss and only modestly reduce the rate of decline. It is also clear that genetic and environmental factors affect risk of Alzheimer's, but scientists haven't figured out why some people with the same risk factors develop the disease while others do not. Lithium, the study authors said, may be a critical missing link.'The idea that lithium deficiency could be a cause of Alzheimer's disease is new and suggests a different therapeutic approach,' said senior author Bruce Yankner, professor of genetics and neurology in the Blavatnik Institute at HMS, who in the 1990s was the first to demonstrate that amyloid beta is study raises hopes that researchers could one day use lithium to treat the disease in its entirety rather than focusing on a single facet such as amyloid beta or tau, he of the main discoveries in the study is that as amyloid beta begins to form deposits in the early stages of dementia in both humans and mouse models, it binds to lithium, reducing lithium's function in the brain. The lower lithium levels affect all major brain cell types and, in mice, give rise to changes recapitulating Alzheimer's disease, including memory authors identified a class of lithium compounds that can evade capture by amyloid beta. Treating mice with the most potent amyloid-evading compound, called lithium orotate, reversed Alzheimer's disease pathology, prevented brain cell damage, and restored the findings need to be confirmed in humans through clinical trials, they suggest that measuring lithium levels could help screen for early Alzheimer's. Moreover, the findings point to the importance of testing amyloid-evading lithium compounds for treatment or lithium compounds are already used to treat bipolar disorder and major depressive disorder, but they are given at much higher concentrations that can be toxic, especially to older team found that lithium orotate is effective at one-thousandth that dose — enough to mimic the natural level of lithium in the brain. Mice treated for nearly their entire adult lives showed no evidence of lithium has not yet been shown to be safe or effective in protecting against neurodegeneration in humans, Yankner emphasises that people should not take lithium compounds on their own. But he expressed cautious optimism that lithium orotate or a similar compound will move forward into clinical trials in the near future and could ultimately change the story of Alzheimer's treatment. 'My hope is that lithium will do something more fundamental than anti-amyloid or anti-tau therapies, not just lessening but reversing cognitive decline and improving patients' lives,' he said. Source: Aletihad - Abu Dhabi
